Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity

Pharmacotherapy

Volumn 20, Issue 2, 2000, Pages 182-190

  Matzke, Gary R ^a,b   Frye, Reginald F ^a   Early, John J ^c   Straka, Robert J ^e   Carson, Stanley W ^c,d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYMETHYLPHENAZONE; 4 HYDROXYPHENAZONE; CAFFEINE; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; PHENACETIN O DEETHYLASE; PHENAZONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ACETYLATION; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPYRINE; ANTITUSSIVE AGENTS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DIABETES MELLITUS, TYPE 2; FEMALE; HALF-LIFE; HUMANS; LIVER; MALE; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES;

EID: 0033972616     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.3.182.34775     Document Type: Article

References (36)

1. Barnett CR, Gibson GG, Wolf CR, Flatt PR, Ioannides C. Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. Biochem J 1990;268:765-9.
2. Longhurst PA, LaCagnin LB, Staats DA, Colby HD. Changes in hepatic drug metabolism in alloxan-diabetic male rabbits. Biochem Pharmacol 1986;35:1768-71.
3. Schenkman JB. Induction of diabetes and evaluation of diabetic state on P450 expression. Methods Enzymol 1991;206:325-31.
4. Chawalit K, Sretarugsa P, Thithapandha A. Comparative effects of diabetogenic agents on hepatic drug metabolism. Drug Metab Dispos 1982;10:81-6.
5. Shafrir E. Diabetes in animals. In Rifkin H, Porte D, eds. Diabetes mellitus: theory and practice. New York: Elsevier Science, 1990:299-340.
6. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991;20(6):477-90.
7. Daintith H, Stevenson IH, O'Malley K. Influence of diabetes mellitus on drug metabolism in man. Int J Clin Pharmacol 1976;13:55-8.
8. Adithan C, Danda D, Shashindran CH, Bapna JS, Swaminathan RP, Chandrasekar S. Differential effect of type I and type II diabetes mellitus on antipyrine metabolism. Methods Find Exp Clin Pharmacol 1989;11:755-8.
9. Murali KV, Adithan C, Shashindran CH, Gambhir SS, Chandrasekar S. Antipyrine metabolism in patients with diabetes mellitus. Clin Exp Pharmacol Physiol 1983;10:7-13.
10. Zysset T, Wietholtz H. Differential effect of type I and type II diabetes on antipyrine disposition in man. Eur J Clin Pharmacol 1988;34:369-75.
11. Salmela PI, Sotaniemi EA, Pelkonen RO. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus. Diabetes 1980;29:788-94.
12. Salmela PI, Sotaniemi EA, Niemi M, Maentausta O. Liver function tests in diabetic patients. Diabetes Care 1984; 7:248-54.
13. Poulsen HE, Loft S. Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J Hepatol 1988;6:374-82.
14. Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37(suppl):40S-8.
15. Teunissen MWE, De Leede LGJ, Boeijinga JK, Breimer DD. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single dose administration and at steady state. J Pharmacol Exp Ther 1985;233:770-4.
16. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996;59(6): 613-23.
17. Danhof M, Groot-van der Vis E, Breimer DD. Assay of antipyrine and its primary metabolites in plasma, saliva, and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology 1979;18:210-23.
18. Frye RF, Stiff DD, Branch RA. A sensitive method for the simultaneous determination of caffeine and its dimethylxanthine metabolites in human plasma: application to CYP1A2 phenotyping. J Liquid Chromatogr Rel Tech 1998;21(8): 1161-71.
19. Tang BK, Kadar D, Qian L, Iriak J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of caffeine use for acetylator phenotyping. Clin Pharmacol Ther 1991;49:648-57.
20. Marshall P, Johnson K, Straka R. The determination of dextromethorphan and its O-demethylated metabolite dextrorphan from urine. Ther Drug Monit 1992;14:402-7.
21. Kalar W, Tang B. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53:503-14.
22. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogenetics 1994;4:109-16.
23. Kilbane AJ, Silbart LK, Manis M, Beitins IZ, Weber WW. Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol Ther 1990;47:470-7.
24. Straka RJ, Hansen SR, Walker PF. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin Pharmacol Ther 1995;58:29-34.
25. Goldstein S, Simpson A, Saenger P. Hepatic drug metabolism is increased in poorly controlled insulin dependent diabetes mellitus. Acta Endocrinol 1990;123:550-6.
26. Shobha JC, Raghurma TC, Dumar AD, Krishnaswamy K. Antipyrine kinetics in undernourished diabetics. Eur J Clin Pharmacol 1991;41:359-61.
27. Yamazoe Y, Muryama N, Shimada M, Yamauchi K, Kato R. Cytochrome P450 in livers of diabetic rats: regulation by growth hormone and insulin. Arch Biochem Biophys 1989;268:567-75.
28. Ioannides C, Bass SL, Ayrton AD, Trinick J, Walker R, Flatt PR. Streptozotocin-induced diabetes modulates the metabolic activation of chemical carcinogens. Chem Biol Interact 1988;68:189-202.
29. Bellward GD, Chang T, Rodrigues B, et al. Hepatic cytochrome P-450 induction in the spontaneously diabetic BB rat. Mol Pharmacol 1987;33:140-3.
30. Barnett CR, Flatt PR, Ioannides C. Induction of hepatic microsomal P450 I and IIB proteins by hyperketonaemia. Biochem Pharmacol 1990;40:393-7.
31. Thummel KE, Schenkman JB. Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol 1991;37: 119-29.
32. Barnett CR, Wilson J, Wolf CR, Flatt PR, Ioannides C. Hyperinsulinaemia causes a preferential increase in hepatic P4501A2 activity. Biochem Pharmacol 1992;43:1255-61.
33. Adithan C, Sriram G, Swaminathan RP, Krishnan M, Bapna JS, Chandrasekar S. Effect of type II diabetes mellitus on theophylline elimination. Int J Clin Pharmacol Ther Toxicol 1989;27(5):258-60.
34. Bechtel YC, Joanne C, Grandmottet M, Bechtel PR. The influence of insulin-dependent diabetes on the metabolism of caffeine and the expression of the debrisoquin oxidation phenotype. Clin Pharmacol Ther 1988;44:408-17.
35. Klebovich I, Rautio A, Salonpaa P, Arvela P, Pelokonen O, Sotaniemi EA. Antipyrine, coumarin and glipizide affect N-acetylation measured by caffeine test. Biomed Pharmacother 1995;5:225-7.
36. Suhardjono D, Boutagy J, Shenfield GM. The effect of glucose on acetylation status. Br J Clin Pharmacol 1986;22:401-8.